中国临床药学杂志

参考文献

[1]Niitsu T,Iyo M,Hashimoto K.Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases[J].Curr Pharm Des,2012,18(7):875.

[2]Furuse T,Hashimoto K.Fluvoxamine monotherapy for psychotic depression:the potential role of sigma-1 receptors[J].Ann Gen Psychiatry,2009,8:26.

[3]Maurice T,Su TP.The pharmacology of sigma-1 receptors[J].Pharmacol Ther,2009,124(2):195.

[4]Stahl SM.Antidepressant treatment of psychotic major depression:potential role of the sigma receptor[J].CNS Spectr,2005,10(4):319.

[5]Hayashi T,Su TP.An update on the development of drugs for neuropsychiatric disorders:focusing on the sigma 1 receptor ligand[J].Expert Opin Ther Targets,2008,12(1):45.

[6]Narita N,Hashimoto K,Tomitaka S,et al.Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain[J].Eur J Pharmacol,1996,307(1):117.

[7]Paschos KA,Veletza S,Chatzaki E.Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression[J].CNS Drugs,2009,23(9):755.

[8]Bermack JE,Debonnel G.Modulation of serotonergic neurotransmission by short-and long-term treatments with sigma ligands[J].Br J Pharmacol,2001,134(3):691.

[9]Maurice T,Roman FJ,Su TP,et al.Beneficial effects of sigma agonists on the age-related learning impairment in the senescence-accelerated mouse(SAM)[J].Brain Res,1996,733(2):219.

[10]Kulkarni SK,Dhir A.Sigma-1 receptors in major depression and anxiety[J].Expert Rev Neurother,2009,9(7):1021.

[11]Hayashi T,Su TP.Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+)signaling and cell survival[J].Cell,2007.131(3):596.

[12]Hindmarch I,Hashimoto K.Cognition and depression:the effects of fluvoxamine,a sigma-1 receptor agonist,reconsidered[J].Hum Psychopharmacol,2010,25(3):193.

[13]Niitsu T,Shirayama Y,Fujisaki M,et al.Fluvoxamine improved cognitive impairments in a patient with schizophrenia[J].Prog Neuropsychopharmacol Biol Psychiatry,2010,34(7):1345.

[14]Furuse T,Hashimoto K.Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease[J].Ann Gen Psychiatry,2010,9:6.

[15]Iyo M,Shirayama Y,Watanabe H,et al.Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia[J].Prog Neuropsychopharmacol Biol Psychiatry,2008,32(4):1072.

[16]Silver H.Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia[J].Expert Opin Pharmacother,2004,5(10):2053.

[17]Hindmarch I,Hashimoto K.Cognition and depression:the effects of fluvoxamine,a sigma-1 receptor agonist,reconsidered[J].Hum Psychopharmacol,2010,25(3):193.

[18]Furuse T,Hashimoto K.Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease[J].Ann Gen Psychiatry,2010,9:6.

[19]Hashimoto K,Furuse T.Sigma-1 receptor agonist fluvoxamine for delirium in older adults[J].Int J Geriatr Psychiatry,2012,27(9):981.

[20]Gorenstein C,de Carvalho SC,Artes R,et al.Cognitive performance in depressed patients after chronic use of antidepressants[J].Psychopharmacology(Berl),2006,185(1):84.

[21]温盛霖,程敏锋,岳计辉.氟伏沙明和氯丙咪嗪对强迫症患者疗效和认知功能的影响[J].中华临床医师杂志(电子版),2010,4(3):297.

[22]徐俊冕.抗抑郁药在老年人群中的应用[J].世界临床药物,2013,34(4):197.

[23]米晶晶.氟伏沙明与阿米替林治疗抑郁症对照研究[J].中西医结合心脑血管病杂志,2011,09(10):1220.

[24]梁胜林,曹世林,谢渭根.氟伏沙明和氟西汀治疗老年期抑郁症的对照研究[J].实用医学杂志,2010,26(9):1620.

[25]胡雪梅,袁日强,钟远惠,等.氟伏沙明与阿米替林治疗老年期抑郁症疗效分析[J].实用医学杂志,2011,27(20):3762.

[26]Kitagishi Y,Kobayashi M,Kikuta K,et al.Roles of PI3K/AKT/GSK3/m TOR Pathway in Cell Signaling of Mental Illnesses[J].Depress Res Treat,2012,752563.